354 Results
Sort By:
Published on July 13, 2020
A large prostate cancer genomics study suggests African-American men, who are disproportionately affected by the cancer, should also benefit from current therapies that target specific genetic mutations causing the disease. However, the researchers—based at Boston University School of Medicine, University of California San Francisco, and Northwestern University—did discover some genetic…
Published on March 23, 2020
Scientists at the University of East Anglia (UEA) say they have discovered a new analytical method that helps explain why some prostate cancers are more aggressive, spread to different parts of the body, and ultimately cause death. The team, which published its study, “A novel stratification framework for predicting outcome…
Published on March 18, 2020
The General Services Administration (GSA) announced it has secured a 10-year reimbursement contract with Exosome Diagnostics laboratory, a Bio-Techne brand, covering its ExoDx Prostate (EPI) test for men. The contract will make EPI available as a reimbursed test to approximately 9 million additional men working in more than 140 government…
Published on March 11, 2020
Prostate cancer is the second most common type of cancer among men. In 2018 alone, about 1.27 million new cases were registered, almost 360,000 patients died. Currently, there are two methods usually used to prove the diagnosis: the prostate-specific antigen (PSA) blood test and the tissue biopsy—taking the tissue samples…
Published on September 27, 2019
Semen could be considered a liquid biopsy of the organs of male reproductive system—specifically, of the prostate gland. This is convenient. Semen is, potentially, a source of prostate disease-specific molecules, which are of intense interest because they could lead to better diagnostic tests. If so, semen-based tests could augment or…
Published on September 16, 2019
Myriad Genetics said today it will assess the clinical utility of its Prolaris test in men diagnosed with prostate cancer, through a collaboration with the Leeds Centre for Personalised Medicine and Health (LCPMH) whose value was not disclosed. Myriad and LCPMH plan to partner on a study designed to evaluate the…
Published on July 18, 2019
Researchers have discovered the mechanism by which a recently described subtype of aggressive prostate cancer spreads, even after treatment with next-generation androgen receptor (AR) inhibitors. They also report pre-clinical results in which they combine an inhibitor molecule with current immunotherapy drugs in mouse models to halt metastasis – even reversing…
Published on May 9, 2019
Investigators at the Yale University School of Medicine have uncovered a potential new biomarker that may identify patients at increased risk of prostate cancer metastasis. Findings from the new study were published recently in The American Journal of Pathologythrough an article titled “Syntaphilin Is a Novel Biphasic Biomarker of Aggressive…
Published on May 6, 2019
MDxHealth has presented positive data designed to demonstrate the accuracy and decision-making value of its two prostate cancer tests, ConfirmMDx and SelectMDx. The molecular diagnostics developer has highlighted a clinical utility study showing that ConfirmMDx had a significant positive impact on repeat prostate biopsy decision-making in a US community urology…
Published on March 25, 2019
Anixa Biosciences said today that for its ongoing study assessing the effectiveness of its Cchek artificial intelligence (AI)-based liquid biopsy in prostate cancer, the company will partner with the Hunter Holmes McGuire VA Medical Center (VAMC) in Richmond, VA. Cchek is Anixa’s platform for a series of inexpensive non-invasive blood…
Published on February 8, 2019
Diagnosing prostate cancer (PCa) has faced hurdles that have been difficult to overcome. The current diagnostic standard, the prostate-specific antigen or PSA test, has many limitations—as Richard J. Ablin, Ph.D., discoverer of PSA in 1970, has vociferously argued on countless occasions. Yet, with such limited diagnostic options and the speed…
Published on November 27, 2018
Molecular diagnostics company MDxHealth has announced that the New York State Department of Health granted approval for its liquid biopsy SelectMDx test for Prostate Cancer to be used in the state, now making it available to patients and physicians in all 50 states in the U.S. “We're thrilled to receive…
Published on October 29, 2018
Epic Sciences and Genomic Health announced that Medicare Administrative Contractor Palmetto GBA, has issued a positive final local coverage determination (LCD) for the Oncotype DX AR-V7 Nucleus Detect test. The final LCD recommends Medicare coverage effective December 10, 2018. The test helps determine which patients with metastatic castrate resistant prostate cancer…
Published on October 18, 2018
Scientists in the U.K. and Canada have identified a DNA methylation signature that they claim can distinguish aggressive prostate cancer from more manageable disease, with up to 92% accuracy. The researchers, headed by Norman Maitland, Ph.D., at the University of York’s department of biology, hope that the pattern of 17…
Published on September 24, 2018
Epic Sciences said today its liquid biopsy blood test showed in a study that it can help physicians select prostate cancer patients who are likely to benefit from a Pfizer prostate-specific membrane antigen (PSMA)-targeted therapy candidate known as BIND-014 before the start of treatment. Researchers from Epic and Memorial Sloan…